MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2(-)-Advanced Breast Cancer

Neven, Patrick; Johnston, Stephen R. D.; Toi, Masakazu; Sohn, Joohyuk; Inoue, Kenichi; Pivot, Xavier; Burdaeva, Olga; Okera, Meena; Masuda, Norikazu; Kaufman, Peter A.; Koh, Han; Grischke, Eva-Maria; Conte, PierFranco; Lu, Yi; Haddad, Nadine; Hurt, Karla C.; Llombart-Cussac, Antonio; Sledge, George W.

Publikationsdienste
→
Universitätsbibliographie
→
4 Medizinische Fakultät
→
Dokumentanzeige

« zurück

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2(-)-Advanced Breast Cancer

Autor(en):

Neven, Patrick; Johnston, Stephen R. D.; Toi, Masakazu; Sohn, Joohyuk; Inoue, Kenichi; Pivot, Xavier; Burdaeva, Olga; Okera, Meena; Masuda, Norikazu; Kaufman, Peter A.; Koh, Han; Grischke, Eva-Maria; Conte, PierFranco; Lu, Yi; Haddad, Nadine; Hurt, Karla C.; Llombart-Cussac, Antonio; Sledge, George W.

Tübinger Autor(en):

Grischke, Eva-Maria

Erschienen in:

Clinical Cancer Research (2021), Bd. 27, H. 21, S. 5801-5809

Verlagsangabe:

Philadelphia

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1158/1078-0432.CCR-20-4685

ISSN:

1078-0432